NIB finances Elekta’s R&D activities for cancer care

NIB and the Swedish medical equipment solutions provider Elekta AB have signed a seven-year loan agreement of GBP 90 million (EUR 102 million) to finance R&D costs for the development of new radiotherapy solutions.

Elekta’s research programme for 2021–2025 focuses on the development of radiation therapy and radiosurgery tools, clinical treatment solutions and workflow-enhancing software systems that support the wide spectrum of cancer care.

Part of the programme will be carried out in Sweden. Elekta’s R&D efforts aim to integrate interdisciplinary activities and support cooperation with clinics and academic hospitals. This intends to improve control of radiation physics, radiation dose calculation, software development and deep learning.

“Radiotherapy is one of the most important tools in cancer treatment. Creating knowledge and skill network clusters between industry and academia will lead to new products and processes. Going forward, radiation therapy aims to become more sophisticated, and digital solutions will change how cancer is treated,” says Henrik Normann, NIB President & CEO.

Elekta AB develops clinical solutions and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as medical software solutions. Elekta is headquartered in Stockholm, Sweden, and employs around 4,000 people globally.

NIB is an international financial institution owned by eight member countries: Denmark, Estonia, Finland, Iceland, Latvia, Lithuania, Norway and Sweden. The Bank finances private and public projects in and outside the member countries. NIB has the highest possible credit rating, AAA/Aaa, with the leading rating agencies Standard & Poor’s and Moody’s.

For further information, please contact

Mr Patrick Nylund, Senior Manager, Origination, at +358 10 618 0329, patrick.nylund@nib.int

Ms Lisa-Maria Altenberger, Communications Unit, at +358 10 618 0234, lisa-maria.altenberger@nib.int